天山生物(300313.SZ)逼近漲停創歷史新高 連漲14日累漲509%
格隆匯9月8日丨A股市場的“妖王”天山生物(300313.SZ)即便在停牌核查,監管“喊話”後仍“高燒不退”繼續上漲,今日盤中再度大漲19.46%至34.5元,創歷史新高,總市值達108億元。該股已連漲14個交易日,其中有10個交易日封漲停板,14個交易日內股價從5.66元上漲至34.5元,累漲509%。創業板註冊制試點實施,“漲停板盈利20%”的誘惑,點燃了創業板小市值股的行情。天山生物便是在這波行情中迅速“崛起”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.